Scholar Rock Announces Proposed Public Offering of Common Stock

Rock Announces Proposed Public Offering of Common Stock

Mass.--(BUSINESS WIRE)--Oct. 27, 2020-- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company

focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it

intends to offer and sell in an underwritten public offering $150,000,000 of shares of its common stock. In addition, Scholar

Rock intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock offered

in the public offering. All of the shares are being offered by Scholar Rock. The offering is subject to market and other conditions,

and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Rock intends to use the net proceeds from the offering to advance SRK-015 in Spinal Muscular Atrophy, including costs associated

with preparing for and executing clinical trials (including a Phase 3 clinical trial), SRK-181 in cancer immunotherapy, development

of its preclinical and discovery programs, as well as for working capital and other general corporate purposes.

Morgan Securities LLC, Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the

offering. BMO Capital Markets Corp. is acting as lead manager for the offering.

securities described above are being offered by Scholar Rock pursuant to a shelf registration statement on Form S-3 (No. 333-231920)

that was declared effective by the Securities and Exchange Commission (SEC) on June 10, 2019. A preliminary prospectus supplement

and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website

located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this

offering may be obtained, when available, by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,

1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com;

Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone

at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; or Credit Suisse Securities (USA) LLC, Attention: Prospectus

Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.

press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be

any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to

registration or qualification under the securities laws of that state or jurisdiction.

Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment

of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline

of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases,

including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's approach to targeting the molecular mechanisms

of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies

that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act

in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors

for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient

Rock is a registered trademark of Scholar Rock, Inc.

press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act

of 1995, including, but not limited to, statements regarding Scholar Rock's intention to conduct an offering and sale of

securities, the size of the offering, the completion of the proposed offering and the expected use of proceeds from the proposed

offering. The use of words such as "may," "might," "will," "should," "expect,"

"plan," "anticipate," "believe," "estimate," "project," "intend,"

"future," "potential," or "continue," and other similar expressions are intended to identify

such forward-looking statements. All such forward-looking statements are based on management's current expectations of future

events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely

from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Scholar

Rock's stock price, changes in market conditions and satisfaction of customary closing conditions related to the public

offering and those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly

Report on Form 10-Q for the quarter ended June 30, 2020, as well as discussions of potential risks, uncertainties, and other important

factors in Scholar Rock's subsequent filings with the SEC. Any forward-looking statements represent Scholar Rock's

views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this

press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required

source version on businesswire.com: https://www.businesswire.com/news/home/20201027006194/en/

Morris, 914-204-6412 kathryn@theyatesnetwork.com

Scholar Rock Holding Corporation